Plan B distributor not optimistic about approval

05/5/2004 | Washington Post, The

The president of Barr Laboratories' research division said she does not expect the FDA to switch the controversial morning-after contraceptive from prescription to over-the-counter status because of a lack of communication with the government agency. She said the drug company is still hopeful the agency, whose advisory committee overwhelmingly voted for the switch, would grant an "approvable letter" to allow Barr to make the switch in the future once certain conditions are met.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD